Albemarle Corporation reported fourth‑quarter 2025 net sales of $1.428 billion, up 15.9% year‑over‑year, and full‑year net sales of $5.14 billion, a 15.9% increase from 2024. Adjusted EBITDA rose 7.2% to $268.7 million, while the company posted a net loss attributable to Albemarle of $414.2 million, a sharp reversal from the $75.3 million loss in the same period a year earlier. Non‑GAAP earnings per share were $-0.53, missing the consensus estimate of $-0.40 by $0.13.
Revenue beat expectations by roughly $80 million, driven by strong demand in the Energy Storage segment and a higher mix of high‑margin products. The Energy Storage business, which supplies lithium‑ion battery components, grew 16% year‑over‑year, offsetting modest declines in the Specialties segment. The company’s focus on cost discipline and productivity improvements—$450 million in gains in 2025—helped maintain adjusted EBITDA margins despite the volatile lithium market.
The EPS miss was largely attributable to one‑time charges. A tax‑related item and a write‑down related to the expected Ketjen transaction reduced earnings. The sale of a controlling stake in Ketjen to KPS Capital Partners, announced in October 2025, closed in the first half of 2026 and contributed a $660 million pre‑tax gain, but the associated asset write‑down in Q4 2025 weighed on profitability.
Segment analysis shows the Energy Storage unit delivered $1.43 billion in revenue, up 16% YoY, while the Specialties unit generated $3.71 billion, down 2% YoY. Adjusted EBITDA margin contracted 150 basis points to 19% in Q4 2025, reflecting pricing pressure in the Specialties segment and the impact of the Ketjen write‑down. Nevertheless, the company achieved a 19% margin, slightly above the 18% margin reported in Q4 2024.
Management guided for 2026 with scenario‑based revenue ranges of $4.1–$7.8 billion and adjusted EBITDA ranges of $0.9–$4.4 billion, highlighting sensitivity to lithium prices. The company also announced the idling of the remaining train at its Kemerton lithium hydroxide plant, a move expected to be accretive to adjusted EBITDA from Q2 2026 onward. The divestiture of Ketjen and the exit from the Eurecat joint venture are part of a strategy to strengthen financial flexibility and focus on core lithium‑related businesses.
Investors reacted negatively to the earnings release, with the primary driver being the EPS miss. The loss, driven by tax items and the Ketjen write‑down, raised concerns about profitability despite the revenue beat. The company’s guidance signals cautious optimism, emphasizing the need for lithium price stability to achieve the upper end of its revenue and EBITDA ranges.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.